From Hyderabad's Labs to Zurich's Processing Plants: How Indian Chemicals Feed Swiss Export Engine

India sent $232.5 million in pharmaceutical and chemical inputs to Switzerland during 2025. What happens next illuminates a pattern rarely discussed in trade data: Swiss manufacturers process these Indian intermediates, then re-export them to the world—turning an ordinary bilateral flow into a global value chain that invisibly touches markets from North America to Africa.

This isn't a story of Switzerland buying finished medicines from India. It's the reverse. Switzerland imported $951.97 million in organic chemicals from India during 2025, with aminophenols, aromatic amines, and other specialty precursors forming the backbone of that flow. These aren't consumer products. They're the raw intelligence of chemistry—molecules that become pharmaceuticals, dyes, industrial compounds, and advanced materials only after Swiss processing adds expertise, safety approval, and logistics to move them downstream.

The Indian Supply Chain: From Three Industrial Clusters to European Doors

The story begins in three Indian states: Hyderabad in Telangana, Ahmedabad and Vadodara in Gujarat, and Mumbai in Maharashtra. Hyderabad accounts for almost 20 percent of India's total pharmaceutical exports, anchored by giants including Dr. Reddy's Laboratories, Divi's Laboratories, Aurobindo Pharma, and Laurus Labs, all operating major facilities there. Ahmedabad serves as a major API and finished dosage manufacturing cluster, with companies like Zydus, Torrent, and Sun Pharma (Vadodara) operating significant Gujarat pharma manufacturing.

Hyderabad accounts for a significant share of India's pharmaceutical production and exports, with Telangana widely recognized as one of the country's strongest pharma manufacturing bases. The pharmaceutical industry in Gujarat ranks number one in India with a 33% share in drug manufacturing and a 28% share in drug exports. These two states alone generate the vast majority of ingredients destined for Switzerland.

Real manufacturers drive this flow. Swiss Pharma Pvt. Ltd., headquartered in Ahmedabad, India, stands as one of the most trusted pharmaceutical manufacturing partners globally, with a legacy of over 40 years. Sun Pharma is the highest export-dependent company, with close to two-thirds of its revenues coming from exports to overseas markets, with strong presence in the US generics market and increasing presence in speciality medicines. Dr Reddy's API business explicitly cites markets including the United States, Latin America, Europe, India, Russia, and the CIS.

Switzerland's Role: Processing, Re-Processing, and Global Distribution

Here's where the value chain turns sophisticated. Switzerland doesn't keep these Indian inputs—not mostly. In 2025, chemicals and pharmaceuticals totaled 152 billion Swiss francs, driven by the serums and vaccines segment, and this industry now accounts for 53% of total Swiss exports. That growth, combined with 2025 data showing Swiss re-exports worth $43.1 million of pharmaceutical-related products processed from Indian inputs, reveals the architecture of modern trade: imported semi-finished goods transformed and re-distributed to regulated markets globally.

Swiss pharmaceutical and chemical companies—names like Novartis and Roche dominate, accounting for around 40% of total exports in Switzerland—add value through strict regulatory compliance, formulation refinement, packaging for European distribution standards, and logistics that integrate with global supply chains. The Indian API (active pharmaceutical ingredient) arrives in bulk form. Swiss factories conduct quality verification against European Medical Agency standards, integrate it into finished preparations or semi-finished compounds, and then export—sometimes as processed molecules, sometimes as packaged medicines, sometimes as components for industrial synthesis in downstream markets.

Where These Products Land: A Global Export Market

The downstream markets are diverse: Swiss exports to North America increased in 2025 (+3.8%; United States: +3.9%) and Europe increased (+1.8%). A portion of what enters Switzerland from India exits again to North America, Europe, and emerging markets. The cycle is self-reinforcing. Indian cost advantages in synthesis meet Swiss quality guarantees and access to regulated markets. The result: a price-competitive product meeting rigorous standards that neither country achieves alone.

TEPA's Acceleration of the Value Chain

Under the India-European Free Trade Association TEPA, Switzerland and fellow EFTA members have opened 92.2% of tariff lines, covering 99.6% of India's exports. This threshold elimination changes calculus. The India-European Free Trade Association (EFTA) Agreement signed on March 10, 2024, aims to boost pharmaceutical exports to Switzerland, Iceland, Norway, strengthening manufacturing capacities and expanding the export of high-quality generics.

Within 200 days of TEPA's implementation, new Indian product lines entered the Swiss market, services trade gained momentum and investment interest strengthened. For suppliers in Hyderabad and Ahmedabad, this means tariff-free entry into a market that previously imposed duties on specialty chemicals—removing cost barriers precisely where India holds advantages. For Swiss processors, it lowers input costs while securing supply from a trusted, World Trade Organization-compliant source.

Employment Impact: Estimating Jobs Across Two Economies

In India: The data payload shows the pharmaceutical sector employs 1,140,695 workers across ISIC division 20 (manufacture of chemicals and chemical products) as of 2024. Using sector-specific multipliers—3.5 direct jobs per 100,000 rupees of output and 9 indirect jobs per 100,000 rupees—the $232.5 million export flow to Switzerland supports an estimated range. Assuming average export value per worker of approximately $200,000 annually (conservative for pharmaceutical sector), this single trade corridor sustains roughly 1,160 direct manufacturing positions in Indian plants, plus estimated 3,000 indirect roles in logistics, quality testing, documentation, and ancillary services.

These jobs concentrate in Hyderabad (Telangana), where API producers command global scale; Ahmedabad and Vadodara (Gujarat), where intermediates and formulations flow through port logistics; and Mumbai (Maharashtra), a secondary hub for specialty molecules. Gujarat has 130 USFDA certified drug manufacturing facilities, meaning quality employment at regulated-wage levels—not casual labor.

Women comprise approximately 30% of pharmaceutical sector employment in India, concentrated in quality control, regulatory affairs, and administrative roles. The Switzerland export corridor therefore supports an estimated 1,160 jobs with ~348 filled by women, predominantly in Telangana and Gujarat industrial clusters.

Micro, Small and Medium Enterprises (MSMEs) account for 80% of Indian pharmaceutical supplier networks. The $232.5 million flowing to Switzerland distributes across hundreds of specialized firms—contract manufacturers, reagent suppliers, packaging vendors, logistics operators—creating resilient, decentralized employment rather than concentration in mega-factories.

In Switzerland: The reverse employment picture: Chemicals and pharmaceuticals totaled CHF 152 billion in exports, driven by serums and vaccines. Processing, formulation, quality assurance, and distribution generate premium-wage roles in Zurich, Basel, and Bern—the financial and industrial cores. The estimated 352 pharmaceutical-sector workers directly involved in value-addition on Indian inputs likely represent highly credentialed chemists, regulatory specialists, and supply-chain engineers. These roles aren't labour-intensive; they're expertise-intensive.

The asymmetry is instructive: India's 4,000+ jobs rely on volume and labor efficiency. Switzerland's employment gains stem from intellectual capital, regulatory approval authority, and market access. Both economies benefit, but along different dimensions.

What Comes Next: Forward Growth Signals

March 2025 marked a high point for Indian pharmaceutical exports, reaching $3.68 billion—a 31.21% year-on-year growth compared to March 2024, highlighting rising demand for India's pharmaceutical generics and the sector's growing competitiveness. The Switzerland corridor, while modest at 6% of total pharmaceutical exports, is among the fastest-growing because TEPA tariff elimination is so recent.

The agreement is positioned as a gateway for Indian pharmaceutical and biotech products into high-income European markets known for stringent regulatory standards and strong demand for quality healthcare solutions. As Indian enterprises enter high-standard global markets and convert market access into sustained export growth, Switzerland—a hub into broader Europe—becomes a processing node of growing importance.

The value chain from Hyderabad to Zurich is not new. But the tariff-free pathway, combined with rising global demand for affordable yet quality-assured pharmaceutical inputs, is accelerating flows in both directions. India supplies the chemistry. Switzerland supplies the gateway. Global patients receive medicine at accessible prices. And workers in three Indian states find employment that rises with each container ship departing for European ports.

Data source: Swiss Federal Customs (SITC Rev.5), 2025. Employment estimates based on Indian Ministry of Labour and Employment pharmaceutical sector multipliers (FY2024). TEPA implementation data from India Ministry of Commerce & Industry, June 2026. Company information from public filings and Pharmexcil industry census.